Linker Nhe I GAT CCA GCA GCT GGG CTC GAG GTG CTA GCG GGA GGG GGT GGA TGT GGG G G G Α E A T G L Α Xa hu IgG1 **♦** Hind III Factor Xa ATC GAA GGT CGC AAG CTT ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT C P C T Н L \mathbf{T} K R G GAA GCC GAG GGG GCA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG 97 P V F S P G Α E Α E GAC ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG 145 C E P T S \mathbf{R} D GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC 193 F K E Р E H GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC 241 R 'K T K Α N H AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC 289 H L S V V V R Y S TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC 337 S K V C \mathbf{E} Y K K G W CCA GCC TCC ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA 385 A K S I \mathbf{T} K E I S P Α GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG 433 E P S Y T AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC 481 G K V Ļ C S ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG 529 N E Q G N S E W E ACC ACG CCT CCC GTG TTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC 577 F S G S D D P V P \mathbf{T} \mathbf{T} AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA 625 V G Q W R S K D V TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC E A L H N H Y T Q K CTC TCC CTG TCT CCG GGT AAA TGA C P G K S

FIG. 1A

.

١.




FIG. 1B




FIG. 1C

Service Servic

The state of the s

1 GGA TCC GGG ATG AAG AAC CTT TCA TTT CCC CTC CTT TTC CTT TTC CTT TTC CTT

M K N L S F P L L F L F L F L F L

52 GTC CCT GAA CTG CTG GGC TCC AGC AGC ATG CCA CTG TGT CCC ATC GAT GAA GCC

V P E L L G S S S M P L C C P I D E A

103 ATC GAC AAG AAG AAG ATC AAA CAA GAC TCC TCC ACC TCC TCC ATC AAT GCA ATA

1 D K K I K Q D F N S L F P N A I

154 AAG AAC ATT GGC TTA AAT TGC TGG ACA GTC TCC TCC AGC AGG AGG TTG ACC

K N I G L N C N T V S S R R G AAG TTG GCC

5 C P E G T A V L S C TTG AGC TCC TCC TCC AGG AGG AGG TTG ACC

205 GGC TCG TGG GAC ATT CGT GAA GAA AAA GTG TGT TGC TCC TCC TGT GCC TGT

256 GGC TCG TGG GAC ATT CGT GAA GAA AAA GTG TGT TGT CAC TGC TGT GCA AGG

G S W D I R E E K V C C H CC GCT TCC TCC TCC AGG TGT TCC TCT

ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG TGT CAC GCT TCC TCC AGG TGT TCC TCT CTA

ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CTG CAG GTC GCT TCC TCT CTA

ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CTG CAG GTC GCT TCC TCT CTA

ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA

ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA

ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA

ATA GAC TGG ACA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA

358 GCG GGA GGG GGT GGA TGT GGG ATC GAA GGT CGC AAG CTT ACT

A G G G C G I E G R K L T

FIG. 2A

M K N L S F P L L F L F L 52 GTC CCT GAA CTG CTG GGC TCC AGC ATG CCA CTG TGT CCC ATC GAT GAA GCC V P E L L G S S M P L C P I D E A 103 ATC GAC AAG AAG ATC AAA CAA GAC TTC AAC TCC CTG TTT CCA AAT GCA ATA I D K K I K Q D F N S L F P N A I 154 AAG AAC ATT GGC TTA AAT TGC TGG ACA GTC TCC TCC AGA GGG AAG TTG GCC K N I G L N C W T V S S R G K L A 205 TCC TGC CCA GAA GGC ACA GCA GTC TTG AGC TGC TCC TGT GGC TCT GCC TGT SCPEGTAVLSCSCGSA 256 GGC TCG TGG GAC ATT CGT GAA GAA AAA GTG TGT CAC TGC CAG TGT GCA AGG G S W D I R E E K V C H C Q C A R 307 ATA GAC TGG ACA GCA GCC CGC TGC TGT AAG CTG CAG GTC GCT TCC TCT CTA I D W T A A R C C K L Q V A S S L 358 GCG GGA GGG GGT GGA TGT GGG GAC GAT GAC GAC AAG CTT ACT A G G G C G D D D K L T

FIG. 2B






FIG. 2C





В

FIG. 3A

FIG. 3B




FIG. 4A

FIG. 4B

5




FIG. 4C

1 2 3 4 5 6 7 8 9




FIG. 5



. ...

FIG. 6




Fig 7

No think the

FIG. 8A




FIG. 8B




FIG. 8C

•. •




FIG. 8D




FIG. 9A

Serum IgG specific for Der p I p52 peptide





FIG. 9B

Serum IgG specific for Der p I p117 peptide



lgG antib dies specific f r human VEGFR-2 peptide




FIG. 10B






FIG. 11




FIG. 12




FIG. 13A




FIG. 13B

66

29

20

14

S

~

FIG. 13C

Sulfo SMPH






FIG. 13D





S

FIG. 14A




FIG. 14B




FIG. 14C




FIG. 15A






FIG. 15B







A




FIG. 16 A




FIG. 16 B




FIG. 17 A




FIG. 17 B




FIG. 18 A




FIG. 18 B




FIG. 18 C




FIG. 18 D




FIG. 18 E




FIG. 18 F




FIG. 19 A

,




FIG. 19 B

S rum antibody titers in vaccinated APP23 mice




FIG. 20




FIG. 21

٠.

Fig Qb mut S-MBS Flag




FIG. 22 A




FIG. 22 B




FIG. 22 C

Fig Qβ mutants-PLA₂-Cys




FIG. 22 D





FIG. 23



Temperature after challenge with PLA2




FIG. 25 A




FIG. 25 B




FIG. 26




FIG. 27 A

 $\boldsymbol{\cdot} = \boldsymbol{\cdot}^{\prime} \boldsymbol{\cdot} \cdot \boldsymbol{\cdot}$

Survival of mice vaccinated intravenesly followed by a lethal influenza A challenge

 $\triangleleft \triangleleft \triangleleft$

4

1

9

Survival	30 VLP	VLP 0/3	9/0	
Immunization	M2 coupled to VLP	M2 fused to VLP	Control	

2

က

FIG. 27 B

M2

M2-VLP

Control




FIG. 28 A




FIG. 28 B